Trillium Therapeutics Provides Corporate Update

NEXT STORY
Kura Oncology’s Menin-MLL Inhibitor KO-539 Receives Orphan Drug Designation from FDA for Treatment of Acute Myeloid Leukemia
PREV STORY
CUSM Class of 2023 Focused on Service and Healthcare for All
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

MacroGenics Provides Update on Corporate Progress and 2015 Financial Results

Eight molecules in clinical development, including six in immuno-oncology Multi-national Phase 1b/2 gastric cancer study ...

author_avatar
NASDAQ Market News

Curetis kündigt Teilnahme an wichtigen Investoren- und Wissenschaftskonferenzen im zweiten Quartal 2017 an

Curetis kündigt Teilnahme an wichtigen Investoren- und Wissenschaftskonferenzen im zweiten Quartal 2017 an Amsterdam, ...

author_avatar
NASDAQ Market News

PAVmed Adds EsoCure™ Esophageal Ablation Device with Patented Caldus™ Technology to Commercial Product Pipeline

author_avatar
NASDAQ Market News